Clin Transplant Res.  2024 Mar;38(1):46-51. 10.4285/kjt.23.0058.

Hepatitis D virus reactivation in liver-transplanted patients receiving hepatitis B immunoglobulin

• Ganbold A
• Bayarsaikhan S
• Chimedtseren M
• Noronrenchin O
• Ochirkhuree B

• KMID: 2555996
• DOI: http://doi.org/10.4285/kjt.23.0058

Abstract

Background
The utility of hepatitis B immunoglobulin (HBIg) in hepatitis D virus (HDV)-reactivation prophylaxis remains contentious. This study compared liver transplant (LT) patients based on whether they received perioperative HBIg to assess its protective effect against HDV reactivation.
Methods
Fifty-seven recipients with hepatitis B virus (HBV) and HBV/HDV, who were at least 1 year posttransplantation as of January 1, 2021, were enrolled in this single-center study. Tests for hepatitis B surface antigen (HBsAg), anti-HDV antibody, and quantitative reverse transcription polymerase chain reaction for HBV DNA and HDV RNA were performed. Interviews were conducted to assess compliance with the nucleos(t) ide analogue (NA) regimen and to document preoperative HBV/HDV status. Liver function tests were also carried out. The nonparametric Mann-Whitney U-test was utilized to determine statistical significance, with P<0.05 considered significant. Data analysis was conducted using GraphPad Prism software.
Results
The prevalence of HDV RNA, HBV DNA, HBsAg, and anti-HDV positivity in the HBIg group (n=23) was 4.3% (n=1), 17.4% (n=4), 8.7% (n=2), and 95.7% (n=22), respectively. In the non-HBIg group (n=34), these rates were 5.9% (n=2), 8.8% (n=3), 11.8% (n=4), and 97.1% (n=33), respectively. Interviews revealed that all reactivations occurred in patients who were noncompliant with their NA regimen. Eleven of the 13 patients initially reported to be monoinfected with HBV pretransplantation were anti-HDV-positive.
Conclusions
No HDV replication occurred in either group due to spontaneous reactivation. High-efficacy NAs appear to be effective in sustaining HDV suppression postLT. Most recrudescent cases of chronic hepatitis D are mild and self-limiting, typically resolving after 1–2 years of replication, as evidenced by liver function tests.

Keyword

Hepatitis B virus; Hepatitis D virus reactivation; Hepatitis B immunoglobulin; Liver transplantation

Reference

1. Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, et al. 1992; Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 33:1390–6. DOI: 10.1136/gut.33.10.1390. PMID: 1446866. PMCID: PMC1379610.

2. Serin A, Tokat Y. 2019; Recurrence of hepatitis D virus in liver transplant recipients with hepatitis B and D virus-related chronic liver disease. Transplant Proc. 51:2457–60. DOI: 10.1016/j.transproceed.2019.01.163. PMID: 31405744.

3. Adil B, Fatih O, Volkan I, Bora B, Veysel E, Koray K, et al. 2016; Hepatitis B virus and hepatitis D virus recurrence in patients undergoing liver transplantation for hepatitis B virus and hepatitis B virus plus hepatitis D virus. Transplant Proc. 48:2119–23. DOI: 10.1016/j.transproceed.2016.02.076. PMID: 27569956.

4. Ottobrelli A, Marzano A, Smedile A, Recchia S, Salizzoni M, Cornu C, et al. 1991; Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology. 101:1649–55. DOI: 10.1016/0016-5085(91)90404-9. PMID: 1955130.

5. Karataylı E, Altunoğlu YÇ, Karataylı SC, Alagöz SG, Cınar K, Yalçın K, et al. 2014; A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. J Clin Virol. 60:11–5. DOI: 10.1016/j.jcv.2014.01.021. PMID: 24594080.

6. Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, et al. 2014; Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun. 443:808–13. DOI: 10.1016/j.bbrc.2013.12.052. PMID: 24342612.

7. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, et al. 2014; Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 60:723–31. DOI: 10.1016/j.jhep.2013.11.022. PMID: 24295872.

8. Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. 2016; Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 65:490–8. DOI: 10.1016/j.jhep.2016.04.016. PMID: 27132170.